Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Oral nanatinostat and valganciclovir for EBV-associated lymphomas

Pierluigi Porcu • 19 Jul 2019
ICML 2019
Lymphoma Viral Lymphoma Nanatinostat Valganciclovir

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, speaking from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland, explains the Phase Ib/II study of oral nanatinostat and valganciclovir in patients with EBV-associated lymphomas (NCT03397706).

More from Pierluigi Porcu

2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023
3:18
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu • 16 Jun 2023
4:17
Nanatinostat and valganciclovir for EBV-associated lymphoma
Pierluigi Porcu • 6 Dec 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals